AU2013209952B2 - New forms and salts of a dihydropyrrolo(1,2-c)imidazolyl aldosterone synthase or aromatase inhibitor - Google Patents

New forms and salts of a dihydropyrrolo(1,2-c)imidazolyl aldosterone synthase or aromatase inhibitor Download PDF

Info

Publication number
AU2013209952B2
AU2013209952B2 AU2013209952A AU2013209952A AU2013209952B2 AU 2013209952 B2 AU2013209952 B2 AU 2013209952B2 AU 2013209952 A AU2013209952 A AU 2013209952A AU 2013209952 A AU2013209952 A AU 2013209952A AU 2013209952 B2 AU2013209952 B2 AU 2013209952B2
Authority
AU
Australia
Prior art keywords
salt
phosphate salt
crystalline form
degrees
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013209952A
Other languages
English (en)
Other versions
AU2013209952A1 (en
Inventor
Eric Loeser
Paul Sutton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati SA
Original Assignee
Recordati SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47604250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013209952(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati SA filed Critical Recordati SA
Publication of AU2013209952A1 publication Critical patent/AU2013209952A1/en
Application granted granted Critical
Publication of AU2013209952B2 publication Critical patent/AU2013209952B2/en
Assigned to RECORDATI AG reassignment RECORDATI AG Request for Assignment Assignors: NOVARTIS AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2013209952A 2012-01-17 2013-01-15 New forms and salts of a dihydropyrrolo(1,2-c)imidazolyl aldosterone synthase or aromatase inhibitor Active AU2013209952B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261587280P 2012-01-17 2012-01-17
US61/587,280 2012-01-17
PCT/US2013/021521 WO2013109514A1 (en) 2012-01-17 2013-01-15 New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor

Publications (2)

Publication Number Publication Date
AU2013209952A1 AU2013209952A1 (en) 2014-07-24
AU2013209952B2 true AU2013209952B2 (en) 2016-09-01

Family

ID=47604250

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013209952A Active AU2013209952B2 (en) 2012-01-17 2013-01-15 New forms and salts of a dihydropyrrolo(1,2-c)imidazolyl aldosterone synthase or aromatase inhibitor

Country Status (40)

Country Link
US (2) US9334276B2 (enExample)
EP (1) EP2804863B1 (enExample)
JP (1) JP5749410B2 (enExample)
KR (2) KR20140093726A (enExample)
CN (1) CN104039793B (enExample)
AP (1) AP2014007762A0 (enExample)
AR (1) AR089728A1 (enExample)
AU (1) AU2013209952B2 (enExample)
BR (1) BR112014017260A8 (enExample)
CA (1) CA2863339C (enExample)
CL (1) CL2014001863A1 (enExample)
CO (1) CO7000775A2 (enExample)
CR (1) CR20140345A (enExample)
CU (1) CU20140086A7 (enExample)
CY (1) CY1117914T1 (enExample)
DK (1) DK2804863T3 (enExample)
EA (1) EA026232B1 (enExample)
ES (1) ES2564143T3 (enExample)
GT (1) GT201400155A (enExample)
HR (1) HRP20160178T1 (enExample)
HU (1) HUE026984T2 (enExample)
IL (1) IL233541B (enExample)
IN (1) IN2014DN06781A (enExample)
JO (1) JO3137B1 (enExample)
MA (1) MA35858B1 (enExample)
MX (1) MX2014008686A (enExample)
NZ (1) NZ626277A (enExample)
PE (1) PE20142358A1 (enExample)
PH (1) PH12014501638A1 (enExample)
PL (1) PL2804863T3 (enExample)
RS (1) RS54589B1 (enExample)
SG (1) SG11201404061YA (enExample)
SI (1) SI2804863T1 (enExample)
SM (1) SMT201600083B (enExample)
TN (1) TN2014000256A1 (enExample)
TW (1) TWI609869B (enExample)
UA (1) UA114803C2 (enExample)
UY (1) UY34576A (enExample)
WO (1) WO2013109514A1 (enExample)
ZA (1) ZA201404314B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011205290C1 (en) * 2010-01-14 2014-11-06 Recordati Ag Use of an adrenal hormone-modifying agent
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
SI3166596T1 (sl) * 2014-07-07 2018-10-30 Novartis Ag Farmacevtske odmerne oblike
HUE054248T2 (hu) 2015-01-29 2021-08-30 Recordati Ag Eljárás kondenzált imidazo-származékok elõállítására
US20160287565A1 (en) * 2015-04-06 2016-10-06 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
EP3532056A1 (en) * 2016-10-27 2019-09-04 Damian Pharma AG Aldosterone synthase inhibitor
WO2018078049A1 (en) * 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
WO2019211394A1 (en) 2018-05-03 2019-11-07 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007024945A1 (en) * 2005-08-25 2007-03-01 Novartis Ag Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase
WO2011088188A1 (en) * 2010-01-14 2011-07-21 Novartis Ag Use of an adrenal hormone-modifying agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1315449A (en) * 1918-11-15 1919-09-09 Frank B Yingling Shaper-feed.
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US5066656A (en) 1989-11-01 1991-11-19 Janssen Pharmaceutica N.V. Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
MTP1076B (en) 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
CA2127689A1 (en) 1992-01-27 1993-08-05 Marcel A. C. Janssen Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors
CA2505752A1 (en) 2002-11-18 2004-06-03 Novartis Ag Imidazo[1,5a]pyridine derivatives and methods for treating aldosterone mediated diseases
CN101578272A (zh) 2006-12-18 2009-11-11 诺瓦提斯公司 1-取代的咪唑衍生物和它们作为醛固酮合酶抑制剂的用途
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007024945A1 (en) * 2005-08-25 2007-03-01 Novartis Ag Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase
WO2011088188A1 (en) * 2010-01-14 2011-07-21 Novartis Ag Use of an adrenal hormone-modifying agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAIRA, M. R., Topics in Current Chemistry, 1998, vol 198, pages 163-208 *

Also Published As

Publication number Publication date
HRP20160178T1 (hr) 2016-03-25
TN2014000256A1 (en) 2015-09-30
JO3137B1 (ar) 2017-09-20
JP5749410B2 (ja) 2015-07-15
PH12014501638B1 (en) 2014-10-13
NZ626277A (en) 2015-10-30
CO7000775A2 (es) 2014-07-21
CU20140086A7 (es) 2014-12-26
IL233541A0 (en) 2014-08-31
IL233541B (en) 2018-12-31
PL2804863T3 (pl) 2016-06-30
RS54589B1 (sr) 2016-08-31
PE20142358A1 (es) 2015-01-30
BR112014017260A2 (pt) 2017-06-13
MX2014008686A (es) 2014-08-27
CR20140345A (es) 2014-09-09
TWI609869B (zh) 2018-01-01
EP2804863B1 (en) 2015-12-02
ES2564143T8 (es) 2020-11-18
US20140364470A1 (en) 2014-12-11
AU2013209952A1 (en) 2014-07-24
EP2804863A1 (en) 2014-11-26
JP2015503627A (ja) 2015-02-02
UA114803C2 (uk) 2017-08-10
ES2564143T3 (es) 2016-03-18
CL2014001863A1 (es) 2014-11-07
UY34576A (es) 2013-09-02
CY1117914T1 (el) 2017-05-17
SG11201404061YA (en) 2014-08-28
EA026232B1 (ru) 2017-03-31
AR089728A1 (es) 2014-09-10
US20160176883A1 (en) 2016-06-23
CA2863339C (en) 2021-03-23
SI2804863T1 (sl) 2016-05-31
GT201400155A (es) 2017-09-28
IN2014DN06781A (enExample) 2015-05-22
DK2804863T3 (en) 2016-03-07
US9334276B2 (en) 2016-05-10
KR20140093726A (ko) 2014-07-28
EA201491374A1 (ru) 2014-12-30
PH12014501638A1 (en) 2014-10-13
ZA201404314B (en) 2015-08-26
CA2863339A1 (en) 2013-07-25
WO2013109514A1 (en) 2013-07-25
SMT201600083B (it) 2016-04-29
BR112014017260A8 (pt) 2017-07-04
CN104039793B (zh) 2017-05-10
HUE026984T2 (en) 2016-08-29
HK1198536A1 (en) 2015-05-15
AP2014007762A0 (en) 2014-07-31
KR20140141687A (ko) 2014-12-10
CN104039793A (zh) 2014-09-10
MA35858B1 (fr) 2014-12-01
TW201335161A (zh) 2013-09-01

Similar Documents

Publication Publication Date Title
CA2863339C (en) Forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor
TWI818902B (zh) 用於抑制精胺酸酶活性的組合物及方法
EP4025575B1 (en) Rip1 inhibitory compounds and methods for making and using the same
ES2461967T3 (es) Compuestos de pirrolo[2,3-d]pirimidina
JP2012520311A (ja) Rafキナーゼの阻害のためのピロロ[2,3−b]ピリジン誘導体
US11440918B2 (en) p38α mitogen-activated protein kinase inhibitors
EP4514466A1 (en) Inhibitors of rock2
CZ20032287A3 (cs) Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK)
US8394821B2 (en) Activated blood coagulation factor inhibitor
TW201249858A (en) Substituted indole derivatives
JP2024542212A (ja) 治療薬としてのペプチドチューブリン阻害剤のペプチドコンジュゲート
KR20230117574A (ko) 암 치료를 위한 metap2 억제제 및 cdk4/6 억제제의 조합
TW200838537A (en) Substituted quinazolines
CN112055590A (zh) 用于治疗醛固酮增多症的r-法屈唑
HK1198536B (en) New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor
HK40122633A (zh) Jak抑制剂类似物、制剂及其用途
CN121735905A (zh) 氘代苯甲醇类trpv3抑制剂及其医药用途
EA038517B1 (ru) Композиции и способы ингибирования активности аргиназы

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: RECORDATI AG

Free format text: FORMER OWNER(S): NOVARTIS AG